<div class="m"><picture><source media="(max-width: 767px)" srcset="https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/343/192/470d0b66-COVID.jpg?ve=1&amp;tl=1, https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/686/384/470d0b66-COVID.jpg?ve=1&amp;tl=1 2x"><source media="(min-width: 767px) and (max-width: 1023px)" srcset="https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/672/378/470d0b66-COVID.jpg?ve=1&amp;tl=1, https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/1344/756/470d0b66-COVID.jpg?ve=1&amp;tl=1 2x"><source media="(min-width: 1024px) and (max-width: 1279px)" srcset="https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/931/523/470d0b66-COVID.jpg?ve=1&amp;tl=1, https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/1862/1046/470d0b66-COVID.jpg?ve=1&amp;tl=1 2x"><source media="(min-width: 1280px)" srcset="https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/720/405/470d0b66-COVID.jpg?ve=1&amp;tl=1, https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/1440/810/470d0b66-COVID.jpg?ve=1&amp;tl=1 2x"> <img src="https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2023/03/640/320/470d0b66-COVID.jpg?ve=1&amp;tl=1" alt="Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken on Oct. 7, 2022" width="100%" height="auto"></picture></div> <div class="info"><div class="caption"><p><span>Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken on Oct. 7, 2022</span> <span>(REUTERS/Wolfgang Rattay/Illustration)</span></p></div></div>

<a href="https://www.foxnews.com/health/fda-propose-yearly-covid-vaccines-like-annual-flu-shots-americans" target="_blank">The Food and Drug Administration's panel</a> of external advisers voted 16-to-1 in favor of the drug's benefits outweighing its risk for some adults with mild-to-moderate COVID-19.

U.S. health regulators voted in favor of a full approval for Pfizer's COVID pill Paxlovid. This pill will will help adults who are at high risk of progression to severe virus.

FDA advisers vote in favor of full approval for Pfizer's COVID pill Paxlovid

Loading...